Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06012240 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

A Phase 3 study of Alopecia Areata, sponsored by AbbVie.

Recruiting
Registry status
Phase 3
Development phase
1,500
Enrollment target
20
Study locations

NCT06012240 is a Phase 3 study of Alopecia Areata that is actively recruiting participants, run by AbbVie. The registered enrollment target is 1,500 participants, below the 1,898-participant average among 26 other Alopecia Areata trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06012240, a Phase 3 study of Alopecia Areata, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 3
Development phase
1,500 participants
Enrollment target
20
Study locations

Study Summary

Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adolescent and adult participants with severe AA. Upadacitinib is an approved drug being investigated for the treatment of AA. In Study 1 and Study 2 and Study 4 Period A, participants are placed in 1 of 3 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 5 chance that participants will be assigned to placebo. In Study 1 and Study 2 and Study 4 Period B, participants originally randomized to upadacitinib dose group in Period A will continue their same treatment in Period B. Participants originally randomized to Placebo in Period A will either remain on placebo in Period B, or be randomized in 1 of 2 groups, based off of their Severity of Alopecia Tool (SALT) score. Participants who complete Study 1, Study 2 or Study 4, can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. Around 1500 participants with severe AA will be enrolled in the study at approximately 280 sites worldwide. Participants will receive oral tablets of either upadacitinib or placebo once daily for up to 160 weeks with the potential of being re-randomized into a different treatment group at Weeks 24 and 52. Participants will be followed up for up to 30 days after last study drug dose. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions Studied

Alopecia Areata

Interventions

  • DRUG Placebo
  • DRUG Upadacitinib

Study Locations (20)

California

  • Duplicate_JOSEPH RAOOF MD,INC /ID# 258031 - Encino
  • First OC Dermatology /ID# 259220 - Fountain Valley
  • University of California Irvine /ID# 259096 - Irvine
  • Dermatology Research Associates /ID# 258033 - Los Angeles
  • Stanford University School of Medicine - Redwood City /ID# 259542 - Redwood City
  • Integrative Skin Science and Research /ID# 258114 - Sacramento
  • University of California Davis Health /ID# 258112 - Sacramento
  • Clinical Trials Research Institute /ID# 258021 - Thousand Oaks

Florida

  • Skin Care Research Boca Raton /ID# 258012 - Boca Raton
  • Apex Clinical Trials /ID# 259205 - Brandon
  • Florida Academic Dermatology Center /ID# 259353 - Coral Gables
  • Skin Research Institute LLC /ID# 259207 - Coral Gables
  • Revival Research /ID# 259213 - Doral
  • Skin Care Research - Hollywood /ID# 259210 - Hollywood
  • GSI Clinical Research, LLC /ID# 259352 - Margate

Arizona

  • Duplicate_Advanced Research Associates - Glendale /ID# 259108 - Glendale
  • Southwest Skin Specialists /ID# 258234 - Phoenix
  • Alliance Dermatology and Mohs Center /ID# 258111 - Phoenix

Alabama

  • Total Skin and Beauty Dermatology Center /ID# 259539 - Birmingham

Arkansas

  • Johnson Dermatology Clinic /ID# 259103 - Fort Smith

Trial Details

FieldValue
Enrollment Target 1,500 participants
Start Date 2023-10-11
Est. Completion 2028-01
Phase Phase 3

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06012240

The ClinicalTrials.gov registry entry for NCT06012240 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,898-participant average among 26 other Alopecia Areata trials with a reported enrollment target (21% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alopecia Areata appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06012240 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06012240 about?

NCT06012240 is a clinical study titled "A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata". Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the head and face, but hair loss can happen on any part of the body. The purpose of this study is to assess how safe, effective, and tolerable upadacitinib is in adol...

What is the current status of trial NCT06012240?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,500 participants. The study started on 2023-10-11. Estimated completion is 2028-01.

What conditions does trial NCT06012240 study?

This clinical trial studies the following conditions: Alopecia Areata.

What interventions are being tested in trial NCT06012240?

The interventions under investigation include: Placebo (DRUG), Upadacitinib (DRUG).

Who is sponsoring clinical trial NCT06012240?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06012240 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alopecia Areata

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alopecia Areata

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.